ALSO NOTED: Korean pharma mired in family feud; Boston Scientific implant gets EU nod;

> Dong-A Pharmaceutical asked Korean authorities to investigate its former chief executive for embezzlement. The nation's top drug maker has been embroiled in a family feud for control for years. Report

> European regulators approved Boston Scientific's new defibrillator known as Confient. Release

> SkyePharma appointed Jeremy Scudamore as non-executive chairman of its board, replacing Jerry Karabelas. Report

> Indian drug maker Cipla and Ugandan partner Quality Chemicals opened a new factory to produce HIV/AIDS meds in the African country. Report

> QLT agreed to take over ForSight Newco, an ocular product company, for $42 million; the deal includes a novel drug-delivery system using "punctal plugs" for a variety of eye conditions. Release

> GlaxoSmithKline is buying into Anacor Pharmaceuticals' research work, inking a deal to in-license boron-containing small molecule anti-infective drug candidates. Report

> Chemistry-related skills are in demand, which is translating to some attractive salaries in the research field. Report

> The Nobel Prize for medicine has gone to three researchers in recognition of their collective work on gene targeting, a process that allows researchers to turn genes off and on in mice. Report

> The market for insomnia drugs in the U.S. is growing at a whopping 29 percent per year, hitting $4.6 billion in 2006 and attracting the attention of a wide range of drug developers. Report

And Finally... Should the FDA allow behind-the-counter drug sales? Poll

Suggested Articles

Merck KGaA has big plans for a site in Switzerland where it intends to knit together biologics development and manufacturing. 

Biocon’s key biosimilars plant in Bengaluru, India, has gotten mixed reviews from the FDA and has now received a Form 483 with five observations.

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?